Jeffrey R Bishop1, Fedra Najjar, Leah H Rubin, Stephen J Guter, Thomas Owley, Matthew W Mosconi, Suma Jacob, Edwin H Cook. 1. aDepartment of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy bDepartment of Psychiatry, University of Minnesota College of Medicine, Minneapolis, Minnesota cDepartment of Psychiatry, University of Illinois at Chicago College of Medicine, Chicago, Illinois dDepartments of Psychiatry and Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Abstract
BACKGROUND AND AIM: Selective serotonin reuptake inhibitors such as escitalopram are commonly used to treat patients with autism spectrum disorder (ASD), but there are individual differences in treatment response and tolerability. CYP2C19 encodes the primary enzyme responsible for escitalopram metabolism and we investigated whether polymorphisms in CYP2C19 were related to symptoms and dosing in a pharmacogenetic study of ASD. PARTICIPANTS AND METHODS: Participants completed the Aberrant Behavior Checklist--Community Version (ABC-CV) weekly for 6 weeks. Escitalopram was initiated at a dose of 2.5 mg per day, with weekly increases to 20 mg unless intolerable side-effects occurred. Three CYP2C19 metabolizer groups, including ultrarapid, extensive, and reduced metabolizers, were examined in relation to symptom improvement and tolerated dose. RESULTS: ABC-CV scores improved over the course of treatment (P<0.0001). No differences were identified in the rate of improvement across metabolizer groups for the ABC-CV irritability subscale, which was the primary outcome for clinical symptoms. There was a trend for a metabolizer group by time interaction with respect to dose (P=0.10). This interaction was driven by the linear rate of change from week 1 to study endpoint between the reduced metabolizers and ultrarapid metabolizer groups (P=0.05). Post-hoc analyses identified significant differences in the rate of dose escalation between ultrarapid metabolizers and extensive metabolizers and for ultrarapid metabolizers compared with reduced metabolizers (P's<0.04), whereby ultrarapid metabolizers showed a slower rate of change in dose over time. CONCLUSION: CYP2C19 ultrarapid metabolizers were associated with reduced tolerance to a fixed titration schedule of open-label escitalopram in this ASD study sample. Possible explanations may involve the altered kinetics of faster metabolizers or previously unknown activities of escitalopram metabolites.
BACKGROUND AND AIM: Selective serotonin reuptake inhibitors such as escitalopram are commonly used to treat patients with autism spectrum disorder (ASD), but there are individual differences in treatment response and tolerability. CYP2C19 encodes the primary enzyme responsible for escitalopram metabolism and we investigated whether polymorphisms in CYP2C19 were related to symptoms and dosing in a pharmacogenetic study of ASD. PARTICIPANTS AND METHODS: Participants completed the Aberrant Behavior Checklist--Community Version (ABC-CV) weekly for 6 weeks. Escitalopram was initiated at a dose of 2.5 mg per day, with weekly increases to 20 mg unless intolerable side-effects occurred. Three CYP2C19 metabolizer groups, including ultrarapid, extensive, and reduced metabolizers, were examined in relation to symptom improvement and tolerated dose. RESULTS: ABC-CV scores improved over the course of treatment (P<0.0001). No differences were identified in the rate of improvement across metabolizer groups for the ABC-CV irritability subscale, which was the primary outcome for clinical symptoms. There was a trend for a metabolizer group by time interaction with respect to dose (P=0.10). This interaction was driven by the linear rate of change from week 1 to study endpoint between the reduced metabolizers and ultrarapid metabolizer groups (P=0.05). Post-hoc analyses identified significant differences in the rate of dose escalation between ultrarapid metabolizers and extensive metabolizers and for ultrarapid metabolizers compared with reduced metabolizers (P's<0.04), whereby ultrarapid metabolizers showed a slower rate of change in dose over time. CONCLUSION:CYP2C19 ultrarapid metabolizers were associated with reduced tolerance to a fixed titration schedule of open-label escitalopram in this ASD study sample. Possible explanations may involve the altered kinetics of faster metabolizers or previously unknown activities of escitalopram metabolites.
Authors: Thomas Owley; Laura Walton; Jeff Salt; Stephen J Guter; Marrea Winnega; Bennett L Leventhal; Edwin H Cook Journal: J Am Acad Child Adolesc Psychiatry Date: 2005-04 Impact factor: 8.829
Authors: Thomas Owley; Camille W Brune; Jeff Salt; Laura Walton; Steve Guter; Nelson Ayuyao; Robert D Gibbons; Bennett L Leventhal; Edwin H Cook Journal: Autism Res Date: 2010-02 Impact factor: 5.216
Authors: David A Mrazek; Joanna M Biernacka; Dennis J O'Kane; John L Black; Julie M Cunningham; Maureen S Drews; Karen A Snyder; Susanna R Stevens; Augustus John Rush; Richard M Weinshilboum Journal: Pharmacogenet Genomics Date: 2011-01 Impact factor: 2.089
Authors: Sarah L Logan; Joyce S Nicholas; Laura A Carpenter; Lydia B King; Elizabeth Garrett-Mayer; Jane M Charles Journal: Ann Epidemiol Date: 2012-01 Impact factor: 3.797
Authors: Bryan H King; Eric Hollander; Linmarie Sikich; James T McCracken; Lawrence Scahill; Joel D Bregman; Craig L Donnelly; Evdokia Anagnostou; Kimberly Dukes; Lisa Sullivan; Deborah Hirtz; Ann Wagner; Louise Ritz Journal: Arch Gen Psychiatry Date: 2009-06
Authors: Staffan Ohlsson Rosenborg; Jessica Mwinyi; Maria Andersson; R Michael Baldwin; Rasmus Steen Pedersen; Sarah C Sim; Leif Bertilsson; Magnus Ingelman-Sundberg; Erik Eliasson Journal: Eur J Clin Pharmacol Date: 2008-07-25 Impact factor: 2.953
Authors: Kazunari Yoshida; Emiko Koyama; Clement C Zai; Joseph H Beitchman; James L Kennedy; Yona Lunsky; Pushpal Desarkar; Daniel J Müller Journal: Can J Psychiatry Date: 2020-11-23 Impact factor: 5.321
Authors: Tatjana Huebner; Michael Steffens; Roland Linder; Jochen Fracowiak; Daria Langner; Marco Garling; Felix Falkenberg; Christoph Roethlein; Willy Gomm; Britta Haenisch; Julia Stingl Journal: BMJ Open Date: 2020-04-27 Impact factor: 2.692
Authors: Stacey L Aldrich; Ethan A Poweleit; Cynthia A Prows; Lisa J Martin; Jeffrey R Strawn; Laura B Ramsey Journal: Front Pharmacol Date: 2019-02-19 Impact factor: 5.810
Authors: Timothy A Roberts; Jennifer A Wagner; Tracy Sandritter; Benjamin T Black; Andrea Gaedigk; Stephani L Stancil Journal: Clin Transl Sci Date: 2020-10-15 Impact factor: 4.689